MiraiBio, BioSource to Develop Assays Using Luminex Technology | GenomeWeb

NEW YORK, March 29 – MiraiBio and BioSource International said Thursday they have agreed to jointly develop biological assays for use in drug discovery using Luminex’s LabMAP technology.

BioSource, based in Camarillo, Calif., will develop assay panels related to extracellular signaling, signal transduction, and cytokine research, while MiraiBio, formerly the Genetic Systems Division of Hitachi Software Engineering, will write software to accompany the assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.